Glucotrack, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Selling, general & administrative | — | — | — | — | $139,000 |
| Research and development | $9.8M | $9.5M | $4.7M | $2.0M | $1.8M |
| Operating expenses | $16.1M | $14.5M | $7.1M | $4.4M | $4.0M |
| Operating income | -$16.1M | -$14.5M | -$7.1M | -$4.4M | -$4.0M |
| Interest expense | — | $44,000 | — | — | — |
| Net income | -$19.4M | -$22.6M | -$7.1M | -$4.4M | -$4.1M |
| Balance Sheet | |||||
| Cash and equivalents | $7.4M | $5.6M | $4.5M | $2.3M | $6.1M |
| Current assets | $7.7M | $5.8M | $4.9M | $2.4M | $6.1M |
| Total assets | $7.8M | $5.9M | $4.9M | $2.4M | $6.3M |
| Current liabilities | $4.8M | $1.3M | $1.5M | $1.0M | $883,000 |
| Total liabilities | $5.0M | $18.9M | $1.7M | $1.2M | $1.1M |
| Stockholders' equity | $2.8M | -$13.0M | $3.2M | $1.2M | $5.2M |
| Cash Flow Statement | |||||
| Cash from operations | -$15.2M | -$12.5M | -$6.6M | -$3.7M | -$3.8M |
| Depreciation and amortization | $42,000 | $36,000 | $13,000 | $23,000 | $42,000 |
| Stock-based compensation | $211,000 | $173,000 | $281,000 | $439,000 | $223,000 |
| Capital expenditure | $96,000 | $104,000 | — | $1,000 | $5,000 |
| Free cash flow | -$15.3M | -$12.6M | — | -$3.7M | -$3.8M |
Shares outstanding 6.3M · Free float 55.8%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.